187 related articles for article (PubMed ID: 33626965)
1. Weight Gain in Incarcerated Individuals Living With HIV After Switching to Integrase Strand Inhibitor-Based Therapy.
Goldberg RN; Kania AT; Michienzi SM; Patel M; Badowski ME
J Int Assoc Provid AIDS Care; 2021; 20():2325958221996860. PubMed ID: 33626965
[TBL] [Abstract][Full Text] [Related]
2. Generally rare but occasionally severe weight gain after switching to an integrase inhibitor in virally suppressed AGEhIV cohort participants.
Verboeket SO; Boyd A; Wit FW; Verheij E; Schim van der Loeff MF; Kootstra N; van der Valk M; Reiss P;
PLoS One; 2021; 16(5):e0251205. PubMed ID: 33951089
[TBL] [Abstract][Full Text] [Related]
3. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts.
Byonanebye DM; Polizzotto MN; Maltez F; Rauch A; Grabmeier-Pfistershammer K; Wit F; De Wit S; Castagna A; d'Arminio Monforte A; Mussini C; Wasmuth JC; Fontas E; Abela I; Sarcletti M; Bansi-Matharu L; Jaschinski N; Peters L; Hosein SR; Vannappagari V; Cohen C; Bissio E; Mocroft A; Law M; Ryom L; Petoumenos K;
Lancet HIV; 2024 May; 11(5):e321-e332. PubMed ID: 38621392
[TBL] [Abstract][Full Text] [Related]
4. An assessment of weight change associated with the initiation of a protease or integrase strand transfer inhibitor in patients with human immunodeficiency virus.
Chow W; Donga P; Côté-Sergent A; Rossi C; Lefebvre P; Lafeuille MH; Emond B; Hardy H
Curr Med Res Opin; 2020 Aug; 36(8):1313-1323. PubMed ID: 32459155
[TBL] [Abstract][Full Text] [Related]
5. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV.
Burns JE; Stirrup OT; Dunn D; Runcie-Unger I; Milinkovic A; Candfield S; Lukha H; Severn A; Waters L; Edwards S; Gilson R; Pett SL
AIDS; 2020 Jan; 34(1):109-114. PubMed ID: 31567162
[TBL] [Abstract][Full Text] [Related]
6. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
[TBL] [Abstract][Full Text] [Related]
7. Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women.
Kerchberger AM; Sheth AN; Angert CD; Mehta CC; Summers NA; Ofotokun I; Gustafson D; Weiser SD; Sharma A; Adimora AA; French AL; Augenbraun M; Cocohoba J; Kassaye S; Bolivar H; Govindarajulu U; Konkle-Parker D; Golub ET; Lahiri CD
Clin Infect Dis; 2020 Jul; 71(3):593-600. PubMed ID: 31504324
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience with weight gain among pregnant women living with HIV who are using integrase inhibitors.
Fuller T; Fragoso da Silveira Gouvêa MI; Benamor Teixeira ML; Ferreira Medeiros A; Amorim da Silva P; Medeiros Braga C; Constan Werneck Sant'anna M; de Mattos Salgueiro M; da Silveira Bressan C; Mendes-Silva W; João EC
HIV Med; 2023 Mar; 24(3):301-310. PubMed ID: 36065478
[TBL] [Abstract][Full Text] [Related]
9. Weight gain following switch to integrase inhibitors from non-nucleoside reverse transcriptase or protease inhibitors in people living with HIV in the United States: analyses of electronic medical records and prescription claims.
Tse J; Prajapati G; Zhao X; Near AM; Kumar PN
Curr Med Res Opin; 2023 Sep; 39(9):1237-1246. PubMed ID: 37480288
[TBL] [Abstract][Full Text] [Related]
10. Metabolic Changes Associated With the Use of Integrase Strand Transfer Inhibitors Among Virally Controlled Women.
Summers NA; Lahiri CD; Angert CD; Aldredge A; Mehta CC; Ofotokun I; Kerchberger AM; Gustafson D; Weiser SD; Kassaye S; Konkle-Parker D; Sharma A; Adimora AA; Bolivar H; Cocohoba J; French AL; Golub ET; Sheth AN
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):355-362. PubMed ID: 33060420
[TBL] [Abstract][Full Text] [Related]
11. Incidence of cardiometabolic outcomes among people living with HIV-1 initiated on integrase strand transfer inhibitor versus non-integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States.
Rebeiro PF; Emond B; Rossi C; Bookhart BK; Shah A; Caron-Lapointe G; Lafeuille MH; Donga P
J Int AIDS Soc; 2023 Jun; 26(6):e26123. PubMed ID: 37306118
[TBL] [Abstract][Full Text] [Related]
12. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
[TBL] [Abstract][Full Text] [Related]
13. Contribution of integrase inhibitor use, body mass index, physical activity and caloric intake to weight gain in people living with HIV.
Guaraldi G; Milic J; Bacchi E; Carli F; Menozzi M; Franconi I; Raimondi A; Ciusa G; Masi V; Belli M; Guaraldi S; Aprile E; Mancini M; Mussini C; Lake JE; Erlandson KM
HIV Res Clin Pract; 2022 Nov; 24(1):1-6. PubMed ID: 36883678
[No Abstract] [Full Text] [Related]
14. Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy.
Erlandson KM; Wu K; Lake JE; Samuels DC; Bares SH; Tassiopoulos K; Koethe JR; Brown TT; Leonard M; Benson CA; Haas DW; Hulgan T;
AIDS; 2021 Mar; 35(3):439-445. PubMed ID: 33252493
[TBL] [Abstract][Full Text] [Related]
15. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV.
Guaraldi G; Calza S; Milic J; Calcagno A; Focà E; Rota M; Renzetti S; Celotti A; Siano M; Celesia BM; Piconi S; de Socio GV; Cattelan AM; Orofino G; Riva A; Nozza S; di Perri G
AIDS; 2021 May; 35(6):939-945. PubMed ID: 33635844
[TBL] [Abstract][Full Text] [Related]
18. Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors.
Donga P; Emond B; Shah A; Bookhart BK; Anderson D; Vermette-Laforme M; Rossi C; Lafeuille MH
J Comp Eff Res; 2023 Jan; 12(1):e220147. PubMed ID: 36445208
[No Abstract] [Full Text] [Related]
19. Weight and Body Mass Index Change After Switching to Integrase Inhibitors or Tenofovir Alafenamide Among Women Living with HIV.
Lahiri CD; Xu Y; Wang K; Alvarez JA; Sheth AN; O'Halloran J; Spence AB; Tien P; Gustafson DR; Milam J; Fischl MA; Konkle-Parker D; Adimora AA; Sharma A; Weber KM; Ofotokun I; Rubin LH
AIDS Res Hum Retroviruses; 2021 Jun; 37(6):461-467. PubMed ID: 33231474
[TBL] [Abstract][Full Text] [Related]
20. Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens.
Milic J; Renzetti S; Ferrari D; Barbieri S; Menozzi M; Carli F; Dolci G; Ciusa G; Mussini C; Calza S; Guaraldi G
AIDS; 2022 Oct; 36(12):1643-1653. PubMed ID: 35727163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
